Strongyloidiasis medical therapy

Jump to navigation Jump to search

Strongyloidiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Strongyloidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Strongyloidiasis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Strongyloidiasis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Strongyloidiasis medical therapy

CDC on Strongyloidiasis medical therapy

Strongyloidiasis medical therapy in the news

Blogs on Strongyloidiasis medical therapy

Directions to Hospitals Treating Strongyloidiasis

Risk calculators and risk factors for Strongyloidiasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Ivermectin, thiabendazole, and albendazole are the most effective medicines for treating strongyloidiasis infection. Ivermectin is the drug of choice, and albendazole is considered the least effective. Thiabendazole is not generally used in the U.S. due to adverse events, but it is still used in other countries. All patients with strongyloidiasis (even asymptomatic patients) require treatment. Complete obstruction with inadequate decompression, lack of response within an interval of 24-48 hrs, volvulus, intussusception, or perforation should be managed surgically.

Treatment

All strongyloidiasis infection (symptomatic and asymptomatic) should be treated with antimicrobial therapy. Due to the high rate of reinfection, it is sometimes necessary to repeat antimicrobial therapy.[1]

Uncomplicated strongyloidiasis

  • Preferred regimen (1): Ivermectin 200 μg/kg/day PO q24h for 2 days.[2][3]
    • Note: For immunocompromised patients, several treatment courses at 2-week intervals is recommended.
  • Alternative regimen (1): Thiabendazole 1.5 g PO q24h for 2 consecutive days.
    • Note: The maximum dosage is 3 g/d every 2 days (this dosage is likely to be toxic and needs to be reduced)
    • Note: Cure rates are as high as 87% to 94%, but the drug may not be effective in the disease that is disseminated beyond the gastrointestinal tract.
    • Note: Many patients have gastrointestinal adverse effects, it is used rarely in the U.S. because of adverse effects
  • Alternative regimen (2): Albendazole 400 mg PO bid for 3 days

Complicated strongyloidiasis (Disseminated or hyper-infection syndrome)

  • Preferred regimen (1): Ivermectin 200 μg/kg/d PO q24h orally for at least 7 to 10 days (until larvae are no longer detected in stool, sputum, or urine)
    • Note: For hyper-infection and disseminated disease, adding albendazole (400 mg PO bid for 7 days) to ivermectin may be warranted.

References

  1. Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC, Terashima A, Samalvides F, Pérez-Molina JA, Plana MN (2016). "Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection". Cochrane Database Syst Rev (1): CD007745. doi:10.1002/14651858.CD007745.pub3. PMC 4916931. PMID 26778150.
  2. Archibald LK, Beeching NJ, Gill GV, Bailey JW, Bell DR (1993). "Albendazole is effective treatment for chronic strongyloidiasis". Q J Med. 86 (3): 191–5. PMID 8483992.
  3. "WGO Practice Guideline Management of Strongyloidiasis" (PDF).

Template:WH Template:WS